You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Boehringer Ingelheim
AstraZeneca
Moodys
Colorcon

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,906,898

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,906,898 protect, and when does it expire?

Patent 8,906,898 protects ZERBAXA and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 8,906,898
Title:Solid forms of ceftolozane
Abstract: Novel solid forms of ceftolozane are described, as well as methods for the preparation and use of these solid forms.
Inventor(s): Hwang; You Seok (Windham, NH), Damour; Nicole Miller (Belmont, MA), Duong; Lisa (Lynn, MA), Jurkauskas; Valdas (Cambridge, MA), Moshos; Kristos Adrian (Belmont, MA), Mudur; Sanjay (Woburn, MA), Ovat; Asli (Maynard, MA), Terracciano; Joseph (Concord, MA), Woertink; Jason (Sudbury, MA)
Assignee: Calixa Therapeutics, Inc. (Lexington, MA)
Application Number:14/289,224
Patent Claim Types:
see list of patent claims
Composition; Process; Formulation;

Drugs Protected by US Patent 8,906,898

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,906,898

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014233633   Start Trial
Australia 2016200570   Start Trial
European Patent Office 3049079   Start Trial
Mexico 2016003958   Start Trial
New Zealand 631761   Start Trial
New Zealand 718365   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Johnson and Johnson
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.